Sanofi’s Pending Acquisition of Amunix

Fenwick & West advised Amunix on the deal, while Weil, Gotshal & Manges advised Sanofi.

Amunix, an immuno-oncology company, announced its pending acquisition by Sanofi, a global biopharmaceutical company.

The?acquisition will?help Sanofi accelerate its efforts to expand its contributions to medicines for oncology patients and highlights its commitment to investing in research and discovery platforms. Under the terms of the agreement, Sanofi will acquire Amunix for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones. The transaction closed on February 08, 2022.

Amunix Pharmaceuticals is an immuno-oncology company focused on designing and developing masked T cell engagers and cytokines to bring the promise of these potent immune-activating biotherapeutics to patients with cancers. 

Sanofi is dedicated to supporting people through their health challenges. They are a global biopharmaceutical company focused on human health. They prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering.

Centerview Partners LLC acted as financial advisor to Amunix.

The Fenwick transaction team includes corporate partners Effie Toshav (Picture), Doug Cogen, David Michaels and Amanda Rose, associates Christopher Gorman and Min Ju Park and law clerk Shannon Lieu; executive compensation & employee benefits partner Nancy Chen and associate Christophe Delrieu; technology transactions partner Stefano Quintini and associates Sophia Chen, Jefferson Lin, Kehl Sink, Trisha Hilder, and Monica Kim, staff attorneys Amy Brown, Jalila Sparks and Margaret Nguyen and law clerk Sarah Meyers; and intellectual property litigation law clerk Diana Buck.

The Weil team that advised Sanofi was led by Mergers & Acquisitions partner Michael J. Aiello and included Mergers & Acquisitions partner Matthew Gilroy, Mergers & Acquisitions counsel Kimberly Thibault and Mergers & Acquisitions associates Sarah Grinshtein, Michael Block and Aryi Kohandel-Shirazi. The team also included Tax Head Joseph Pari; Tax partner Graham Magill; Tax counsel Blake Bitter; Tax associate Musa Jemal; Executive Compensation & Benefits Head Paul Wessel; Executive Compensation & Benefits partner Amanda Rosenblum; Executive Compensation & Benefits associate Manleen Singh (Admitted in Illinois Only); Technology & IP Transactions partner Michael Epstein; Technology & IP Transactions Co-Head Jeffrey Osterman; Technology & IP Transactions/Privacy counsel Lauren Springer; Technology & IP Transactions/Privacy associates Catherine Kim, Hui Li, Meggin Bednarczyk and Justin Yun; Environmental Head Annemargaret Connolly; Environmental counsel Thomas Goslin; Regulatory Transactions partner Kevin Sullivan; Regulatory Transactions counsel John O’Loughlin; Regulatory Transactions associate Ariel Fliman; Antitrust Head Steven Newborn; Antitrust partner John Scribner; Antitrust counsel Michael Naughton; Antitrust associate Jarui Wang; Securities Litigation partner Robert Carangelo; Employment Litigation partner Nicholas Pappas; and Employment Litigation associate Nicole Jibrine.

Involved fees earner: Amy Brown – Fenwick & West LLP; Nancy Chen – Fenwick & West LLP; Sophia Chen – Fenwick & West LLP; Douglas Cogen – Fenwick & West LLP; Christophe Delrieu – Fenwick & West LLP; Christopher Gorman – Fenwick & West LLP; Trisha Hilder – Fenwick & West LLP; Jefferson Lin – Fenwick & West LLP; David Michaels – Fenwick & West LLP; Stefano Quintini – Fenwick & West LLP; Amanda Rose – Fenwick & West LLP; Kehl Sink – Fenwick & West LLP; Jalila Sparks – Fenwick & West LLP; Effie Toshav – Fenwick & West LLP; Michael Aiello – Weil, Gotshal & Manges; Meggin Bednarczyk – Weil, Gotshal & Manges; Blake Bitter – Weil, Gotshal & Manges; Michael Block – Weil, Gotshal & Manges; Robert Carangelo – Weil, Gotshal & Manges; Annemargaret Connolly – Weil, Gotshal & Manges; Michael Epstein – Weil, Gotshal & Manges; Ariel Fliman – Weil, Gotshal & Manges; Matthew Gilroy – Weil, Gotshal & Manges; Thomas Goslin – Weil, Gotshal & Manges; Sarah Grinshtein – Weil, Gotshal & Manges; Musa Jemal – Weil, Gotshal & Manges; Nicole Jibrine – Weil, Gotshal & Manges; Catherine Kim – Weil, Gotshal & Manges; Aryi Kohandel-Shirazi – Weil, Gotshal & Manges; Hui Li – Weil, Gotshal & Manges; Graham Magill – Weil, Gotshal & Manges; Michael Naughton – Weil, Gotshal & Manges; Steven Newborn – Weil, Gotshal & Manges; Jeffrey Osterman – Weil, Gotshal & Manges; John O’Loughlin – Weil, Gotshal & Manges; Nicholas Pappas – Weil, Gotshal & Manges; Joseph Pari – Weil, Gotshal & Manges; Amanda Rosenblum – Weil, Gotshal & Manges; John Scribner – Weil, Gotshal & Manges; Manleen Singh – Weil, Gotshal & Manges; Lauren Springer – Weil, Gotshal & Manges; Kevin Sullivan – Weil, Gotshal & Manges; Kimberly Thibault – Weil, Gotshal & Manges; Jarui Wang – Weil, Gotshal & Manges; Paul Wessel – Weil, Gotshal & Manges; Justin Yun – Weil, Gotshal & Manges;

Law Firms: Fenwick & West LLP; Weil, Gotshal & Manges;

Clients: Amunix Pharmaceuticals; Sanofi S.A.;

Martina Bellini

Author: Martina Bellini